Clinical Trial Detail

NCT ID NCT03978611
Title A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Bristol-Myers Squibb
Indications

melanoma

Therapies

Ipilimumab + Relatlimab

Age Groups: senior adult

Additional content available in CKB BOOST